Evidence map›Paper›PMID 35478149›Full record

ArticleIn vivo (Athens, Greece)

ALK Protein Expression Patterns in Squamous Cell Carcinoma of the Oral Cavity.

Aristeidis Chrysovergis, Vasileios Papanikolaou, Nicholas Mastronikolis, Evangelos Tsiambas, Spyros Katsinis, Arezina Manoli, Sotirios Papouliakos, Vasileios Ragos, Pavlos Pantos, Dimitrios Peschos and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Aristeidis ChrysovergisFirst ENT Department, Hippocration Hospital, University of Athens, Athens, Greece.
Vasileios PapanikolaouFirst ENT Department, Hippocration Hospital, University of Athens, Athens, Greece.
Nicholas MastronikolisENT Department, Medical School, University of Patras, Patras, Greece.
Evangelos TsiambasDepartment of Pathology, Immunohistochemistry and Molecular Biology Laboratory, 401 General Army Hospital, Athens, Greece; tsiambasecyto@yahoo.gr.
Spyros KatsinisDepartment of Otorhinolaryngology, Sotiria Thoracic Diseases General Hospital, Athens, Greece.
Arezina ManoliDepartment of Otorhinolaryngology, Sotiria Thoracic Diseases General Hospital, Athens, Greece.
Sotirios PapouliakosDepartment of Otolaryngology, Gennimatas General Hospital, Athens, Greece.
Vasileios RagosDepartment of Maxillofacial, Medical School, University of Ioannina, Ioannina, Greece.
Pavlos PantosFirst ENT Department, Hippocration Hospital, University of Athens, Athens, Greece.
Dimitrios PeschosDepartment of Physiology, Medical School, University of Ioannina, Ioannina, Greece.
Stylianos MastronikolisDepartment of Ophthalmology, Medical School, University of Patras, Patras, Greece.
Panagiotis FotiadesDepartment of Surgery, 424 Army Hospital, Thessaloniki, Greece.
Panagiotis MamoulidisFirst ENT Department, Hippocration Hospital, University of Athens, Athens, Greece.
Despoina SpyropoulouDepartment of Radiation Oncology, Medical School, University of Patras, Patras, Greece.
Efthymios KyrodimosFirst ENT Department, Hippocration Hospital, University of Athens, Athens, Greece.
Hippocration General Hospital · GRUniversity of Ioannina · GRUniversity of Patras · GRSotiria General Hospital · GR424 General Military Hospital · GRGeneral Hospital of Athens Elpis · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral squamous cell carcinoma (OSCC) is characterized by a broad spectrum of genomic imbalances, including gross chromosomal (polysomy/aneuploidy) ones as well as specific gene alterations. Aberrant expression of anaplastic lymphoma kinase (ALK) seems to be a useful molecular marker for discriminating patients based on genetic signatures in a variety of solid malignancies, such as lung carcinoma. Our aim was to analyze ALK protein expression patterns in a series of OSCCs. MATERIALS AND

methodsFifty (n=50) OSCC tissue sections were analyzed by implementing an ALK-based immunohistochemistry protocol. Digital image analysis was performed for measuring the corresponding protein expression levels.

resultsALK overexpression was observed in 14/50 (28%) OSCC tissue sections, whereas the rest 36/50 (72%) demonstrated low expression levels. ALK expression was negatively associated with grade (p=0.027) and stage (p=0.0028) of the examined cases.

conclusionAbnormal ALK expression in subsets of patients with OSCC seems to be related to an aggressive phenotype (advanced stage/progressive dedifferentiation). ALK protein overexpression may be used as a significant marker for applying targeted therapeutic regimens.

Indexed as

Carcinoma, Squamous CellMouth NeoplasmsAnaplastic Lymphoma KinaseHumansReceptor Protein-Tyrosine KinasesALK protein, humanAnaplastic Lymphoma KinaseReceptor Protein-Tyrosine KinasesALKCarcinomageneoral cancerproteintyrosine kinase inhibitors

Identifiers

PMID35478149
PMCPMC9087091
OpenAlexW4225080549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.